PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
MWN-AI** Summary
PURE Bioscience, Inc. (OTCQB: PURE) announced its fiscal first-quarter financial results for the period ending October 31, 2025. The company reported net product sales of $707,000, representing a $152,000 increase from $555,000 in the same quarter last year, attributed to growing sales across its customer base. Despite this sales growth, PURE recorded a net loss of $464,000 for the quarter, an improvement from the $689,000 loss seen in Q1 2024. When excluding share-based compensation, the net loss was $430,000 compared to $632,000 in the previous year.
Notably, the net loss per share remained at ($0.00), which is an improvement from the ($0.01) per share loss reported for the fiscal first quarter of 2024. The company emphasized its continued momentum in key markets, particularly within the produce industry, where its antimicrobial product, PURE Control®, is experiencing significant adoption for treating leafy greens. Additionally, there has been growth in the transportation sector through the deployment of SDC-powered sanitation technology and equipment to major trucking fleets.
President Jeff Kitchell highlighted the positive trajectory of year-over-year sales growth and ongoing efforts to expand their core produce business, as well as collaborations in the beverage and dairy sectors for rolling out membrane treatment solutions.
As of October 31, 2025, PURE's total assets stood at $1.186 million with current liabilities reaching $3.159 million. The company remains committed to advancing its innovative antimicrobial products, primarily targeting safety standards in the food and beverage industries, as it seeks to address health and environmental challenges posed by pathogens.
MWN-AI** Analysis
After reviewing the fiscal first quarter 2026 financial results from PURE Bioscience, it is clear the company is gaining momentum, setting a positive tone for future performance. Net product sales increased to $707,000 from $555,000 year-over-year, reflecting a commendable 27% growth. Such sales traction suggests heightened adoption of PURE's silver dihydrogen citrate (SDC) antimicrobial technology across key markets, particularly in the produce and transportation sectors.
Notably, the reduction in net loss from $689,000 in Q1 2025 to $464,000 in Q1 2026, alongside improvements in operational efficiency, indicates a viable path towards profitability. Moreover, the net loss per share has stabilized to $0.00, which is promising for investor sentiment, given the previous loss of ($0.01) per share.
However, investors should approach with cautious optimism. The increased accounts payable and convertible notes present potential liquidity concerns. The current liabilities have surged to $3.16 million from $938,000, raising questions about the company’s ability to sustain its operations without further financing or revenue growth.
Moreover, while PURE’s growth in the produce sector is affirming, its capacity to translate product evaluations into consistent orders, particularly in the beverage and dairy sectors, is pivotal for sustained growth.
In conclusion, while PURE Bioscience exhibits promising sales growth and a decreasing loss trend, potential investors should monitor cash flow developments and the company's ability to scale operations effectively. Diversifying their product offerings and expanding market reach can enhance future growth prospects. Those considering an investment should weigh the current opportunities against the risks associated with rising liabilities and reliance on continued market acceptance of their products.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal first quarter ended October 31, 2025.
Summary of Results of Operations – Fiscal First Quarter
- Net product sales were $707,000 and $555,000 for the fiscal first quarter ended October 31, 2025 and 2024, respectively. The increase of $152,000 was attributable to increased sales across our end-user customer base.
- Net loss for the fiscal first quarter ended October 31, 2025, was $464,000, compared to $689,000 for the fiscal first quarter ended October 31, 2024.
- Net loss, excluding share-based compensation, for the fiscal first quarter ended October 31, 2025, was $430,000, compared to $632,000 for the fiscal first quarter ended October 31, 2024.
- Net loss per share was ($0.00) and ($0.01) for the fiscal first quarter ended October 31, 2025 and 2024, respectively.
As an update to the press release dated October 29, 2025, the Company is pleased to report continued momentum across its key markets. The Company has made significant strides in expanding its presence within the produce industry. Sales of its seasonal direct food-contact solution, PURE Control®, continue to grow, and the product is now actively being used to treat leafy greens destined for commercial sale, marking an important milestone in market adoption and customer confidence. The Company has also experienced growth in the transportation industry, leveraging its new SDC-powered sanitation technology and equipment to major trucking fleets through its key distribution partners.
Jeff Kitchell, President, stated, “Our fiscal first quarter year-over-year sales growth shows the progress we have made with our direct customers and distribution network. We are continuing to grow our core produce business. At the same time, we are working closely with our distribution partners in the beverage and dairy industry to roll out our new membrane treatment solutions.”
About PURE Bioscience, Inc.
PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing our proprietary antimicrobial products, primarily in the food and beverage industry. We provide solutions to combat the health and environmental challenges posed by pathogens and ensure hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and the mitigation of bacterial resistance. Additional information on PURE is available at www.purebio.com .
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE products into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2025 and Form 10Q for the fiscal first quarter ended October 31, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. Condensed Consolidated Balance Sheets | ||||||||
October 31, 2025 | July 31, 2025 | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 434,000 | $ | 334,000 | ||||
Accounts receivable | 389,000 | 474,000 | ||||||
Inventories, net | 237,000 | 141,000 | ||||||
Restricted cash | 75,000 | 75,000 | ||||||
Prepaid expenses | 41,000 | 23,000 | ||||||
Total current assets | 1,176,000 | 1,047,000 | ||||||
Property, plant and equipment, net | 10,000 | 11,000 | ||||||
Total assets | $ | 1,186,000 | $ | 1,058,000 | ||||
Liabilities and stockholders’ deficiency | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 879,000 | $ | 784,000 | ||||
Convertible notes payable to related parties, current | 2,104,000 | — | ||||||
Accrued liabilities | 176,000 | 154,000 | ||||||
Total current liabilities | 3,159,000 | 938,000 | ||||||
Convertible notes payable to related parties, non-current | 3,573,000 | 5,236,000 | ||||||
Total liabilities | 6,732,000 | 6,174,000 | ||||||
Commitments and contingencies | ||||||||
Stockholders’ deficiency | ||||||||
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding | — | — | ||||||
Common stock, $0.01 par value: 200,000,000 shares authorized, 111,886,473 shares issued and outstanding at October 31, 2025, and July 31, 2025 | 1,119,000 | 1,119,000 | ||||||
Additional paid-in capital | 132,793,000 | 132,759,000 | ||||||
Accumulated deficit | (139,458,000 | ) | (138,994,000 | ) | ||||
Total stockholders’ deficiency | (5,546,000 | ) | (5,116,000 | ) | ||||
Total liabilities and stockholders’ deficiency | $ | 1,186,000 | $ | 1,058,000 |
PURE Bioscience, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||
Three months ended | ||||||||
October 31, | ||||||||
2025 | 2024 | |||||||
Net product sales | $ | 707,000 | $ | 555,000 | ||||
Royalty revenue | 1,000 | 1,000 | ||||||
Total revenue | 708,000 | 556,000 | ||||||
Cost of goods sold | 258,000 | 231,000 | ||||||
Gross Profit | 450,000 | 325,000 | ||||||
Operating costs and expenses | ||||||||
Selling, general and administrative | 743,000 | 881,000 | ||||||
Research and development | 86,000 | 71,000 | ||||||
Total operating costs and expenses | 829,000 | 952,000 | ||||||
Loss from operations | (379,000 | ) | (627,000 | ) | ||||
Other income (expense) | ||||||||
Interest expense, net | (94,000 | ) | (62,000 | ) | ||||
Other income, net | 9,000 | — | ||||||
Total other income (expense) | (85,000 | ) | (62,000 | ) | ||||
Net loss | $ | (464,000 | ) | $ | (689,000 | ) | ||
Basic and diluted net loss per share | $ | (0.00 | ) | $ | (0.01 | ) | ||
Shares used in computing basic and diluted net loss per share | 111,886,473 | 111,856,473 |
PURE Bioscience, Inc. Condensed Consolidated Statement of Stockholders’ Deficiency (Unaudited) | ||||||||||||||||||||
Common Stock | Additional Paid-In | Accumulated | Total Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Deficiency | ||||||||||||||||
Balance July 31, 2025 | 111,886,473 | $ | 1,119,000 | $ | 132,759,000 | $ | (138,994,000 | ) | $ | (5,116,000 | ) | |||||||||
Share-based compensation expense - stock options | — | — | 34,000 | — | 34,000 | |||||||||||||||
Net loss | — | — | — | (464,000 | ) | (464,000 | ) | |||||||||||||
Balance October 31, 2025 (Unaudited) | 111,886,473 | $ | 1,119,000 | $ | 132,793,000 | $ | (139,458,000 | ) | $ | (5,546,000 | ) |
Common Stock | Additional Paid-In | Accumulated | Total Stockholders’ | |||||||||||||||||
Shares | Amount | Capital | Deficit | Deficiency | ||||||||||||||||
Balance July 31, 2024 | 111,856,473 | $ | 1,119,000 | $ | 132,612,000 | $ | (136,595,000 | ) | $ | (2,864,000 | ) | |||||||||
Share-based compensation expense - stock options | — | — | 57,000 | — | 57,000 | |||||||||||||||
Net loss | — | — | — | (689,000 | ) | (689,000 | ) | |||||||||||||
Balance October 31, 2024 (Unaudited) | 111,856,473 | $ | 1,119,000 | $ | 132,669,000 | $ | (137,284,000 | ) | $ | (3,496,000 | ) |
PURE Bioscience, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
Three Months Ended | ||||||||
October 31, | ||||||||
2025 | 2024 | |||||||
Operating activities | ||||||||
Net loss | $ | (464,000 | ) | $ | (689,000 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Share-based compensation | 34,000 | 57,000 | ||||||
Depreciation | 1,000 | — | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 85,000 | (73,000 | ) | |||||
Inventories | (96,000 | ) | (16,000 | ) | ||||
Prepaid expenses | (18,000 | ) | (20,000 | ) | ||||
Accounts payable and accrued liabilities | 117,000 | 178,000 | ||||||
Interest on note payable | 91,000 | 60,000 | ||||||
Net cash used in operating activities | (250,000 | ) | (503,000 | ) | ||||
Financing activities | ||||||||
Net proceeds from note payable to related parties | 350,000 | 500,000 | ||||||
Net cash provided by financing activities | 350,000 | 500,000 | ||||||
Net increase (decrease) in cash and cash equivalents, and restricted cash | 100,000 | (3,000 | ) | |||||
Cash and cash equivalents, and restricted cash at beginning of period | 409,000 | 424,000 | ||||||
Cash and cash equivalents, and restricted cash at end of period | $ | 509,000 | $ | 421,000 | ||||
Reconciliation of cash and cash equivalents, and restricted cash to the condensed consolidated balance sheets | ||||||||
Cash and cash equivalents | $ | 434,000 | $ | 346,000 | ||||
Restricted cash | 75,000 | 75,000 | ||||||
Total cash and cash equivalents and restricted cash | $ | 509,000 | $ | 421,000 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20251215068126/en/
Mark Elliott, VP Finance
PURE Bioscience, Inc.
619-596-8600
FAQ**
How does Pure Bioscience Inc (PURE) plan to leverage its increased sales in the produce industry for future growth, particularly in light of its expanding customer base?
What specific steps is Pure Bioscience Inc (PURE) taking to manage its current liabilities, which have significantly increased since the previous quarter?
Given the reported net loss for Pure Bioscience Inc (PURE), what strategies does the company have in place to achieve profitability in the near term?
How will Pure Bioscience Inc (PURE) address potential competitive challenges, especially concerning the higher cost of SDC-based products compared to traditional treatment chemicals in the marketplace?
**MWN-AI FAQ is based on asking OpenAI questions about Pure Bioscience Inc (OTC: PURE).
NASDAQ: PURE
PURE Trading
-3.85% G/L:
$0.065 Last:
975 Volume:
$0.0676 Open:
